Antifungal drugs: predicting clinical efficacy with pharmacodynamics.

about

Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma.Pharmacokinetic and Pharmacodynamic Properties of Oral Voriconazole in Patients with Invasive Fungal Infections.

P2860

Q37761047-8DC5554E-E779-4C64-90E3-A331F2723CB1 Q40982014-D2F06428-CCEE-45D4-8C4E-5280B3C93C29

P2860

Antifungal drugs: predicting clinical efficacy with pharmacodynamics.

Item

http://www.wikidata.org/entity/Q42723597

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Antifungal drugs: predicting clinical efficacy with pharmacodynamics.

@en

Antifungal drugs: predicting clinical efficacy with pharmacodynamics.

@nl

type

Item

label

Antifungal drugs: predicting clinical efficacy with pharmacodynamics.

@en

Antifungal drugs: predicting clinical efficacy with pharmacodynamics.

@nl

prefLabel

Antifungal drugs: predicting clinical efficacy with pharmacodynamics.

@en

Antifungal drugs: predicting clinical efficacy with pharmacodynamics.

@nl

P1476

Antifungal drugs: predicting clinical efficacy with pharmacodynamics.

@en

P2093

Michael D Nailor

http://www.w3.org/2001/XMLSchema#string

Pranatharthi H Chandrasekar

http://www.w3.org/2001/XMLSchema#string

P2860

Voriconazole therapeutic drug monitoring.

Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America

Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)

Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy.

Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia.

In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model.

Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans

Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole.

Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model

Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.

P304

373-379

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ECP.09.14

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2009-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22112181

http://www.w3.org/2001/XMLSchema#string

Antifungal drugs: predicting clinical efficacy with pharmacodynamics.

about

P2860

P2860

Antifungal drugs: predicting clinical efficacy with pharmacodynamics.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698